2020


2019


Bergsland EK, Mahoney MR, Asmis TR, Hall N, Kunthekar P, Maitland ML, Niedzwiecki D, Nixon AB, O'Reilly EM, Schwartz LH, Strosberg JR, Meyerhardt JA. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive...


- Hotte SJ, Winquist E, Chi KN, Ellard SL, Sridhar S, Emmenegger U, Salim M, Iqbal NN,


- Olson D, Bao R, Allred JB, Strand C, Zha Y, Carlil TC, Labadie B, Bastos BR, Butler MO,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Munster PN, Schwartz GK, Luke JJ. Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib ( cabo) versus chemotherapy ( chemo). J Clin Oncol 37[Suppl; abstr 9505]. 2019.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2018


abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Renouf DJ, Dhani NC, Kavan P, Jonker DJ, Wei AC, Hsu T, Tang PA, Graham B, Gallinaro L, Hasan T, Li W, Hart K, Tu D, O’Callaghan CJ. The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D),


Bradbury P, Melosky B, Tu D, Nicholas G, Wheatley-Price P, Laurie S, Goss G,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. J Clin Oncol 34[suppl; abstr 3621]. 2016.


Blood 128[22], 4162. 16 A.D.


randomized PORTEC-3 trial. J Clin Oncol 33[ suppl; abstr 5501].
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Oncol 33[suppl; abstr 8046].
- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].
- Pennimitt MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

J Clin Oncol 33[suppl; abstr TPS4573].


2014

- Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Hematolological Oncology 31[suppl 1], 96-150. 2013.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[ suppl; abstr 4061], 2013.


2012


- Fehringer G, Liu J, Pintilie M, Sykes J, Liu N, Cheng D, Chen Z, Seymour L, Der SD,


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liaw W, Sawyer M, Jefford M, Magoski NM, Haydon A, Walters I, Tu D, O’Callaghan CJ, on behalf of NCIC CTG and AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


2011


- Chi KN, Eigl BJ, North S, Squire J, Eisenhauer E. A Phase II Study of SB939 in Patients...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

with Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC). Canadian Cancer Research Conference, 2011.


- Goodwin RA, Jamal R, Tu D, Oza AM, Elit L. Predictors of Response and Progression to Temsirolimus in Women with Recurrent or Metastatic Endometrial Cancer. Canadian


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


of progression-free survival as a surrogate endpoint for overall survival when evaluating the effect of chemotherapy and radiotherapy in locally advanced lung cancer using data from four individual patient data meta-analyses. J Thoracic Oncol 6[6 suppl 2, abstr O42.05], S464, 2011.


Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. J Clin Oncol 28[15s,

Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Jamal R, Goodwin RA, Tu D, Walsh W, Eisenhauer EA. Application of multinomial
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Trudeau ME, Clemons MJ, Dent RA, Kahn HJ, Parisenti AM, Chapman JW, O'Brien P,


2009

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Bradbury PA, Addison CL, Goss G, Shepherd FA, Seymour L, Le Maître A, Ding K.
  Baseline TGF- and amphiregulin levels in non small cell lung cancer patients treated
  with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 clinical trial. J Thoracic
  Oncol 4[9 suppl 1, abstr PD9.2.4], S537-S538. 2009.

- Bradbury PA, Twumasi-Ankrah P, Ding K, Shepherd FA, Goss G, Leith NB, Laurie S,
  Seymour L. Known Brain Metastases: A valid exclusion criterion in non-small cell lung
  cancer (NSCLC) clinical trials? An audit of the eligibility criteria in NSCLC trials, and an
  evaluation of treatment delivery, toxicity and survival experienced by patients with brain
  metastases in NCIC clinical trial group trials. J Thoracic Oncol 4[9 suppl 1, abstr A1.7],
  S288. 2009.

- Bradbury PA, Twumasi-Ankrah P, Ding K, Leith NB, Goss GD, Laurie S, Shepherd FA,
  Seymour L. The impact of brain metastases on overall survival in National Cancer
  Institute of Canada Clinical Trials Group clinical trials in advanced non-small cell lung

  W, Ivy SP, Crump M, Eisenhauer E. Sunitinib in relapsed or refractory diffuse large B
  cell lymphoma: results of a phase II multi-center study of the NCIC Clinical Trials Group.
  Blood (ASH Annual Meeting Abstracts) 114[22, abstr 2729], 2009.

- Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO.
  Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant
  CMF to CEF. J Clin Oncol 27[15s], 2009.

- Chen B, Graubard,B, Flegal K, Gail M. Evaluating strategies to estimate the association

  BE. Differential localization of ezrin expression in normal and neoplastic mammary
  tissues. United States and Canadian Academy of Pathology, 2009.

- Chia SK, Ung K, Bramwell V, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Mardis
  E, Cheang M, Pritchard K, Shepherd L, Nielsen TO. Prognostic and predictive impact of
  intrinsic biological classification by immunohistochemistry (IHC) and QPCR for adjuvant
  tamoxifen in pre-menopausal breast cancer: results from the NCIC CTG MA.12 trial.

  E. Final results of a randomized phase II study of OGX-011 in combination with
docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration

  E. Mature results of a randomized phase II study of OGX-011 in combination with
docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-

- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I,
  Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals
  regions of DNA copy number gain that may be predictive of benefit from adjuvant

- da Cunha Santos G, Ding K, Cutz J-C, Le Maître A, Squire JA, Shepherd FA, Tsao MS,
  Seymour L. A novel algorithm for the EGFR fluorescence in situ hybridization (FISH)
  assay in non-small cell lung cancer: an analysis of the NCIC Clinical Trials Group Study

- Dancey JE. Testing for biomarker driven therapy (ERCC1 and EGFR). J Thoracic Oncol
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

4[9 suppl 1, abstr GR3.3], S172-S173. 2009.


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


S504-S505. 2009.


2008


- Bacon M. The evolving role of the nurse in clinical trials: Impact and opportunities.
Clinical Trials Seminar for Nurses (Tokyo), 2008.


• Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


• Song H, Peng Y, Tu D, Niu Y. Testing the homogeneity in two-sample censored mixture model when cure proportion may exist in one group. Statistical Society of Canada, 2008.


• Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Statistical Society of Canada, 2008.


• Burnell M, Levine M, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberga T, Chalchal HI, Albain K, Perez E, Rugo H, Pritchard KI, Ding Z, O'Brien P, Shepherd L. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin alfa followed by paclitaxel versus sequenced AC followed by paclitaxel versus CEF in women with node positive or


- Cigler T, Yaffe MJ, Johnston D, Verma S, Findlay B, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. A placebo-controlled trial examining the effects of


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


Asmis TR, Ding K, Whitehead M, Seymour L, Shepherd FA, Winton T, Leighl N, Goss G.


- El-Maraghi RH, Ellard S, Gelmon K, McIntosh L, Seymour L. Pulmonary changes in a


MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Treatment and Research 100[Suppl 1], S23, 2006.


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


2005


• Eisenhauer EA. Combinations of agents for clinical development: which ones? How and when to develop these? Annals of Oncology 16[Suppl 3], 26, 2005.
• Gauthier I, Seymour L. Target effect and predictors of efficacy using laboratory correlative studies in early clinical trials: The Investigational New Drug Program at the NCIC Clinical Trials Group perspective. CIHR/NCIC National Meeting for Trainees, 2005.


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2005.

- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

- Assouline S, Eisenhauer E. RECIST (Response Evaluation Criteria in Solid Tumors)


Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Fuchs C, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup


Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert NJ, Martino S,


2003


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2002


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Voskoglou-Nomikos T, Pater J, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft pre-clinical cancer models.


• Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical Trials Group randomized controlled trial. Breast Cancer Research and Treatment 69,


Shepherd L, Parulekar W, Day A, Ottaway J, Bramwell V, Levine M, Pritchard K. Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients:


2000


Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D,


- Shepherd FA, Arnold A, Neville A, Cormier Y, Davis M, Wierzbicki R, Dancey J,


1999


1998


Li T, Zee B, James K, Brundage M. Determination of toxicity health states for multiple myeloma patients - a comparison between correspondence analysis and clinicians’


1997


- Cripps C, Burnell M, Jolivet J, Lofters C, Fisher B, Panasci L, Iglesias J, Eisenhauer E. Phase II study of multi-targeted antifolate (LY231514) as first line therapy in patients...


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1996

- Dent S, Zee B, Dancey J, Melnychuck D, Eisenhauer E, Steward W, Lu F. Design of


- Piccart M. Is TP the standard in first-line treatment? The EORTC experience.
Gynecologic Conference, 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Eisenhauer E, Vermorken J, Myles J, van Glabbeke M. Tumour bulk, histology, and baseline hemoglobin may influence response in platinum pretreated ovarian cancer.


- Lofters C, Zee B. Adding 5HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


1994

- Bacon M. Impact and opportunities of clinical trials for cancer nursing. Canadian
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Health-related quality-of-life domains are affected by chemotherapy and extent of disease in patients with lung,


---

1993


- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


Grever M, Kopecky K, Head D, Cassileth P, Golomb H, Habermann T, Rai K, Eisenhauer E, Cheson B. A randomized comparison of deoxycoformycin versus alpha-2a interferon in previously untreated patients with hairy cell leukemia. An NCI-


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


1991


1989

• Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.
**Abstracts**
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


---

**1988**


---

**1987**

- Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Phase II study of intravenous
menogaril as first line chemotherapy for patients with breast cancer. 

- Klaassen D, Shelley W, Starreveld A, Boyes D, Gerulath A, Levitt M, Fraser R, 
  Carmichael J, Methot Y. Early stage ovarian cancer: a randomized clinical trial 
  comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chormic 
  phosphate -- all programs included pelvic radiotherapy. Proc.Am.Soc.Clin.Oncol. 6, 117, 
  1987.

- Logan D, Perrault DJ, Eisenhauer E, Stewart D, White D. Phase I-II study of flutamide in 

- Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans W, Hodson I, Clark D, Feld R, 
  supportive care to two regimens of combination chemotherapy in the management of 

- Yelle L, Willan A, Pater J. Trial of chemotherapy and radiotherapy in advanced 

Band P, Maroun J, Pritchard K, Coppin C, Wilson K, Eisenhauer E. Phase II study of 
lonidamine in advanced breast cancer. NCI Canada Clinical Trials Group. 

Band P, Weinerman B, Eisenhauer E, Murray N. Lonidamine, a new anticancer agent: 

Eisenhauer E, Johnston JB, Barr R, Feldman L, Maksymiuk A, Scott G, Sutton D, 
Venner P, Walde D, Zaentz D. 2'-Deoxycoformycin (DCF) in hairy cell leukemia. NCI-
EORTC Symposium on New Drugs in Cancer Therapy, 1986.

Evans W, Murray N, Feld R, Coy P, Levitt M, MacDonald A, Cormier Y, Young V, Osoba 
D, Shelley W, Willan A. Canadian multicenter randomized trial comparing standard and 
alternating combination chemotherapy in extensive small cell lung cancer. 

P, Walde D. 2'-deoxycoformycin in hairy cell leukemia: a Canadian phase II trial. 

Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I 
1986.

A, Phaneuf D, Pater J. Multicentre comparison of aztreonam plus cloxacillin, aztreonam 
plus tobramycin, or moxalactam plus tobramycin as empiric therapy of febrile 
neutropenic episodes. International Symposium on Infections in the 
Immunocompromised Host, 1986.

O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an 
overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.

Pater J, Elliott C. The effect of different measures of outcome on the results of studies of

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981

• Belch A, Ronald AR, Feld R, Pater J. Efficacy of lithium during remission induction of